sb 203580 has been researched along with dalcetrapib in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (dalcetrapib) | Trials (dalcetrapib) | Recent Studies (post-2010) (dalcetrapib) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 166 | 38 | 103 |
| Protein | Taxonomy | sb 203580 (IC50) | dalcetrapib (IC50) |
|---|---|---|---|
| Cholesteryl ester transfer protein | Homo sapiens (human) | 4.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawamura, A; Matsuo, Y; Miura, S; Saku, K | 1 |
1 other study(ies) available for sb 203580 and dalcetrapib
| Article | Year |
|---|---|
JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27(kip1) and Ras/p21(waf1) pathways.
Topics: Amides; Atherosclerosis; Cell Division; Cells, Cultured; Coronary Vessels; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Endothelium, Vascular; Enzyme Inhibitors; Esters; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; Pyridines; ras Proteins; Sulfhydryl Compounds; Up-Regulation; Vascular Endothelial Growth Factor A | 2005 |